KPRX vs. PPBT, ERNA, RDHL, IMNN, PIRS, HUGE, EDSA, AKTX, MNPR, and ABVC
Should you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Purple Biotech (PPBT), Eterna Therapeutics (ERNA), RedHill Biopharma (RDHL), Imunon (IMNN), Pieris Pharmaceuticals (PIRS), FSD Pharma (HUGE), Edesa Biotech (EDSA), Akari Therapeutics (AKTX), Monopar Therapeutics (MNPR), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical preparations" industry.
Kiora Pharmaceuticals (NASDAQ:KPRX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
Kiora Pharmaceuticals has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
Kiora Pharmaceuticals and Purple Biotech both received 12 outperform votes by MarketBeat users. However, 92.31% of users gave Purple Biotech an outperform vote while only 66.67% of users gave Kiora Pharmaceuticals an outperform vote.
Purple Biotech has a consensus price target of $9.00, indicating a potential upside of 1,524.55%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than Kiora Pharmaceuticals.
Kiora Pharmaceuticals' return on equity of 17.90% beat Purple Biotech's return on equity.
In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Purple Biotech. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.00 beat Kiora Pharmaceuticals' score of -0.52 indicating that Purple Biotech is being referred to more favorably in the news media.
77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 0.9% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Purple Biotech beats Kiora Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Kiora Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiora Pharmaceuticals Competitors List
Related Companies and Tools
